Jazz Pharmaceuticals plc (JAZZ) Stock

Understand Jazz Pharmaceuticals plc: how it makes money

Jazz develops and sells specialty neurological drugs, most notably the oral sodium oxybate solution Xywav for narcolepsy and idiopathic hypersomnia, to a small U.S. patient pool at premium per-patient pricing. Revenue is heavily weighted toward sleep-medicine products, with epilepsy and oncology as secondary commercial lines.

The core economic engine is a premium-priced oral solution sold into a narrow orphan patient pool, producing very high revenue per patient but capping total growth at disease-prevalence limits and leaving the flagship franchise exposed to a single generic entrant.

Business quality (Solid): Solid: 16% top-line growth, 20% operating margin, 21% ROE, and a P/E of 18x that sits only 5% above the industry median. The growth profile is respectable, but the margin structure is compressed relative to pure-play pharma peers because of the controlled-substance supply chain and a shrinking sleep-medicine base.

Valuation: At 18× earnings, JAZZ trades in line with the Pharmaceutical Products average (17×).

Bull case

• Oncology pipeline is inflecting: Zanidatamab (zanidonlimab) showed more than two years of median overall survival in first-line gastroesophageal adenocarcinoma on the Q4 FY25 call, a result that could open a large oncology franchise beyond the neuroscience core.
• Epidiolex is a proven franchise: Management cited Epidiolex reaching blockbuster status with 9% annual growth and $1.1 billion in revenue, giving Jazz a second durable, growing pillar that offsets sleep-medicine softness.
• Valuation lags the growth rate: At 18.0x trailing earnings versus the Pharmaceutical Products industry average of 17.1x (only 5% above), the stock trades at roughly a fair multiple even though revenue is growing 16% year over year, meaning the market has not fully priced in continued execution.

Bear case

• Sleep franchise is guided smaller: Management guided rare-sleep (Xywav and related) revenue down to $1.8 to $1.9 billion for 2026, a clear deceleration from the product's prior trajectory and the largest single line in Jazz's P&L.
• Generics are eroding the crown jewel: Two generic high-sodium Xyrem products are expected to enter the market and further reduce Xyrem/Xywav sales, directly attacking the highest-margin product in the portfolio and compressing the patient-count base that drives the $1.2B quarterly topline.
• Guidance opacity hides risk: Management declined to provide adjusted net income or EPS guidance for 2026, removing the single most important checkpoint investors use to monitor whether cost increases and pipeline spend are being absorbed or passed through.

Jazz Pharmaceuticals plc earnings call transcripts

• JAZZ Q4 FY25 earnings call transcript (reported 2026-02-24) · analysis

All JAZZ earnings calls

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Alnylam Pharmaceuticals, Inc. (ALNY)
• BioMarin Pharmaceutical Inc. (BMRN)
• United Therapeutics Corporation (UTHR)
• Sarepta Therapeutics, Inc. (SRPT)
• PTC Therapeutics, Inc. (PTCT)
• Phibro Animal Health Corporation (PAHC)
• Vertex Pharmaceuticals Incorporated (VRTX)
• Regeneron Pharmaceuticals, Inc. (REGN)